FEATURED CONTENT

Tumor diagnosis recharacterization enabled by comprehensive genomic profiling powered by PGDx to guide precision medicine strategy

Hear experts discuss comprehensive genomic profiling (CGP) via next-generation sequencing (NGS), the standard clinical practice for identifying actionable mutations and genomic signatures to identify cancer patients who may benefit from targeted and immunotherapies, as well as clinical trials.

Learning Objectives

  • Examine and provide expanded evidence for the novel application of CGP as a confirmatory diagnostic tool
  • Demonstrate the utility of CGP for tumor characterization to help improve therapeutic decisions and clinical outcomes
  • Re-evaluate primary diagnoses using CGP based on results
  • Utilize an integrated review strategy to refine, and in some instances, reclassify patient diagnoses to provide more accurate therapeutic recommendations based on updated diagnoses
Speakers Info
Michelle Shiller, DO, MSPT
Medical Director of Genomics and Molecular Pathology Services PathGroup

Michelle Shiller is a thought leader in integrating the clinical use of molecular diagnostics, focusing on effective utility, interpretation and application of testing. She has helped to bridge educational gaps in molecular oncology topics such as targeted therapy, prognostics, techniques, genetic disorders and ethical and legal considerations in genomic medicine in order to break down barriers to implementation and adoption.

Ann Carr, PhD, MSc
Assistant Director of Bioinformatics PathGroup

Watch Webinar

Watch our webinar to learn how Labcorp’s PGDx elio™ plasma focus Dx can accelerate test internalization.

Watch Webinar
RESOURCES

Educational tools to facilitate local comprehensive genomic profiling implementation